论文部分内容阅读
选取2013年2月~2014年12月期间我院收治的68例血糖控制不佳的2型糖尿病患者,分为观察组(n=34)和对照组(n=34)。对照组治疗方案维持不变,观察组在原有基础上加用沙格列汀及吡格列酮。结果:治疗前,两组患者的GLU、2hPG、HbA_(1c)、FINS、FCP、homa-β和homa-IR、Homa-IR(CP)比较无统计学意义(P>0.05);治疗后,观察组患者的GLU、2hPG、HbA_(1c)、FINS和homa-IR、Homa-IR(CP)水平降低,FCP、homa-β升高(P<0.05);对照组无明显变化(P>0.05);FCP显著升高(P<0.05);观察组患者的的GLU、2hPG、HbA_(1c)、FINS和homa-IR、Homa-IR(CP)水平低于对照组,FCP、homa-β高于对照组(P<0.05);两组不良反应无统计学意义(P>0.05)。结论:难治性糖尿病患者可以加用沙格列汀吡格列酮治疗安全有效。
Sixty-eight patients with type 2 diabetes with poor glycemic control admitted to our hospital from February 2013 to December 2014 were selected and divided into observation group (n = 34) and control group (n = 34). The control group treatment plan remained unchanged, the observation group on the basis of the original plus saxagliptin and pioglitazone. Results: Before treatment, the GLU, 2hPG, HbA_ (1c), FINS, FCP, homa-β and homa-IR and Homa-IR in two groups were not statistically significant (P> 0.05) The levels of GLU, 2hPG, HbA_ (1c), FINS and homa-IR, FCP and homa-β in the observation group were significantly lower than those in the control group (P> 0.05 (P <0.05). The levels of GLU, 2hPG, HbA_ (1c), FINS and homa-IR, Homa-IR (CP) in the observation group were lower than those in the control group In the control group (P <0.05). There was no significant difference between the two groups (P> 0.05). Conclusion: Patients with refractory diabetes can be treated with saxagliptin pioglitazone safe and effective.